Toumi N, Ben Kridis W, Mnejja W, Bouzguenda R, Khanfir A, Ghorbel A, Daoud J, Frikha M
Department of Oncology, Habib-Bourguiba Hospital, Sfax, Tunisia.
Department of Oncology, Habib-Bourguiba Hospital, Sfax, Tunisia.
Cancer Radiother. 2018 May;22(3):216-221. doi: 10.1016/j.canrad.2017.10.005. Epub 2018 Apr 9.
We represent in this study the long term results of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy in Tunisian patients with locally advanced nasopharyngeal carcinoma. The objective of our study is to analyse the efficacy as well as the toxicity of this therapeutic protocol.
Between January 2004 and December 2008, 32 patients with locoregional advanced non metastatic disease (T2b or above and/or N1 or above AJCC 2002) were treated in our institution by three cycles of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy every 21 days followed by concurrent chemoradiotherapy. Conventional radiotherapy was delivered using a cobalt 60 machine during 7 weeks with weekly cisplatin (40mg/m).
Twenty-nine patients (90%) had presented an objective clinical response in lymph nodes after neoadjuvant chemotherapy, with a complete response in 28%. Acute toxicity of docetaxel, cisplatin and 5-fluorouracil induction chemotherapy was dominated by vomiting (59%), asthenia (40.6%), diarrhea (34.4%) and febrile neutropenia (15.6%). The complete response rate after the end of treatment was around 80%. The 5 years overall survival and disease-free survival were respectively 68.2% and 67.5%.
Our results, in this field of study, are encouraging with acceptable toxicity despite the lack of intensity-modulated radiotherapy technique in our institution during the period of study.
本研究展示了多西他赛、顺铂和5-氟尿嘧啶诱导化疗,随后对突尼斯局部晚期鼻咽癌患者进行同步放化疗的长期结果。我们研究的目的是分析该治疗方案的疗效和毒性。
2004年1月至2008年12月期间,32例局部区域晚期非转移性疾病(T2b及以上和/或N1及以上,AJCC 2002)患者在我们机构接受治疗,每21天进行三个周期的多西他赛、顺铂和5-氟尿嘧啶诱导化疗,随后进行同步放化疗。使用钴60机器进行常规放疗,为期7周,每周给予顺铂(40mg/m)。
29例患者(90%)在新辅助化疗后淋巴结出现客观临床反应,其中28%完全缓解。多西他赛、顺铂和5-氟尿嘧啶诱导化疗的急性毒性主要表现为呕吐(59%)、乏力(40.6%)、腹泻(34.4%)和发热性中性粒细胞减少(15.6%)。治疗结束后的完全缓解率约为80%。5年总生存率和无病生存率分别为68.2%和67.5%。
在本研究领域,尽管在研究期间我们机构缺乏调强放疗技术,但我们的结果令人鼓舞,毒性可接受。